Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | CCR1 | P32246 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | CCR8 | P51685 | 2/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.50 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31211649 | 1.00 | CYP1A2 (0.59) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL31400240 | 0.89 | CYP1A2 (0.49) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL21988536 | 0.89 | CYP1A2 (0.49) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL26553101 | 0.87 | CYP1A2 (0.48) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL26556299 | 0.87 | CYP1A2 (0.48) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL28426269 | 0.86 | CYP1A2 (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL31039983 | 0.85 | CYP1A2 (0.45) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL3177333 | 0.85 | CYP1A2 (0.60) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL19010901 | 0.84 | TP53 (0.60) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL18466596 | 0.83 | CYP1A2 (0.58) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10151699-B2 | Development of lead ion testing paper with naked-eye observable readout for ten min on-site detection | HONG KONG BAPTIST UNIVERSITY (HK) | 2018-12-11 | — | — | US | claimed |
| US-10145825-B2 | Luminescent Iridium(III) complex and its uses thereof for the G-quadruplex-based switch-on rapid detection of lead ions | HONG KONG BAPTIST UNIVERSITY (HK) | 2018-12-04 | — | — | US | claimed |
| US-20170102330-A1 | Development of lead ion testing paper with naked-eye observable readout for ten min on-site detection | UNIVERSITY OF MACAU (MO) | 2017-04-13 | — | — | US | claimed |
| US-20170102331-A1 | Luminescent Iridium(III) complex and its uses thereof for the G-quadruplex-based switch-on rapid detection of lead ions | HONG KONG BAPTIST UNIVERSITY (HK) | 2017-04-13 | — | — | US | claimed |
| CN-101538289-B | Monomer for organic electro-phosphorescent polymer | XIAN MODERN CHEMISTRY RES INST | 2011-09-28 | — | — | CN | claimed |
| CN-101538289-A | Monomer for organic electro-phosphorescent polymer | XIAN MODERN CHEMISTRY RES INST | 2009-09-23 | — | — | CN | claimed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2023-11-16 | — | — | US | disclosed |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230345811-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230303601-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230287011-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-14 | — | — | US | disclosed |
| EP-4201404-A1 | ANTIVIRAL COMPOUNDS FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | Erasmus University Rotterdam Medical Center (NL) | 2023-06-28 | — | — | EP | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | 3M INNOVATIVE PROPERTIES COMPANY | 2007-07-19 | — | — | US | disclosed |
| US-7192918-B2 | Tripeptide and tetrapeptide sulfones | TELIK, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| US-20050148623-A1 | Prevent reproduct of aids virus | ABBVIE INC. | 2005-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303601-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | MGLL, SELENOI, APOL1 | CYP1A2 2689/4885CYP2D6 1595/4885CYP19A1 2120/4885 |
| US-20050148623-A1 | Prevent reproduct of aids virus | SERPINB1, PRSS1, SERPINA3 | CYP1A2 920/4885CYP2D6 1068/4885CYP19A1 52/4885 |
| US-11806335-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | CYP1A2 514/4885CYP2D6 375/4885CYP19A1 1204/4885 |
| US-20070167476-A1 | Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds | IL4, IL2, IL5 | CYP1A2 1717/4885CYP2D6 2853/4885CYP19A1 2398/4885 |
| US-20230287011-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD2, OXGR1, OCIAD1 | CYP1A2 1490/4885CYP2D6 2724/4885CYP19A1 2219/4885 |
| US-20230365582-A1 | NOVEL COMPOUNDS HAVING INHIBITORY ACTIVITY ON PROSTAGLANDIN E2 RECEPTOR AND USES THEREOF | PTGER1, PTGIR, PTGDR2 | CYP1A2 747/4885CYP2D6 845/4885CYP19A1 304/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | CYP1A2 2459/4885CYP2D6 1947/4885CYP19A1 1299/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | CYP1A2 1181/4885CYP2D6 1134/4885CYP19A1 657/4885 |
| US-20230345811-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OPRD1, L1CAM, OPRM1 | CYP1A2 2224/4885CYP2D6 2100/4885CYP19A1 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.